EP Patent

EP3774902A1 — Anti-trem-1 antibodies and uses thereof

Assigned to Bristol Myers Squibb Co · Expires 2021-02-17 · 5y expired

What this patent protects

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such a…

USPTO Abstract

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3774902A1
Jurisdiction
EP
Classification
—
Expires
2021-02-17
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.